PAR-18-550: Analytical Validation of Candidate Biomarkers for Neurological Disease (U01 Clinical Trial Optional) - 0 views
-
MiamiOH OARS on 02 Jan 18The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use. This FOA assumes that 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding context of use is in place Also listed under U44